VP Diabetes, Obesity, & MASH Pharmacology Research

Novo Nordisk is looking for a visionary leader with a passion for driving scientific innovation to serve as the VP Diabetes, Obesity & MASH Pharmacology Research within our Diabetes, Obesity & MASH Global Research team. With the expertise to lead multifunctional teams and shape the future of cardiometabolic therapies, this role offers an opportunity to make a significant impact. Read on and apply today for a life-changing career.   

The Position

As the VP Diabetes, Obesity, MASH (DOM) Pharmacology Research, you will:

•    Play a key role in leading Pharmacology Research in discovery and evaluation of core biology and novel targets in DOM and cardiometabolic disease with the goal to advance the projects to deliver to the NN pipeline.
•    Serve as a leadership role model, setting direction and driving change management.
•    Play a key role in setting strategy and scientific direction in Diabetes, Obesity, and MASH, integrating data science with biology and in vivo pharmacology.
•    Develop and execute strategic business plans, ensuring global cross-organisational collaboration.
•    Oversee management tasks, including performance management and resource optimisation.
•    Foster collaboration across the value chain and engage with key stakeholders.
•    Ensure quality, compliance, and regulatory responsibilities are met.

Qualifications

We are looking for a candidate with:

•    A PhD in biological sciences or MD
•    Minimum 15 years of relevant experience in scientific research, drug discovery, and development.
•    Proven track record in drug development, preferably within the pharmaceutical industry.
•    Proven track record in people leadership
•    Strong international network and access to key opinion leaders.
•    Exceptional communication skills and the ability to lead by example.
•    Experience in project-oriented, international matrix organisations.

About the organization

Diabetes, Obesity & MASH Global Research (DOMGR) is dedicated to accelerating the development of core and novel cardiometabolic therapies. Based in Greater Boston and Greater Copenhagen, our team collaborates closely with Research & Early Development teams worldwide. We focus on discovering and evaluating targets to modulate diabetes, obesity, MASH and cardiometabolic diseases, driving scientific innovation to support Novo Nordisk’s pipeline aspirations.This position may be located in the US or Denmark. 

Working at Novo Nordisk

Novo Nordisk is a leading global healthcare company with a 100-year legacy of driving change to defeat serious chronic diseases. Building on our strong legacy within diabetes, we are growing massively and expanding our commitment, reaching millions around the world and impacting more than 40 million patient lives daily. All of this has made us one of the 20 most valuable companies in the world by market cap. Our success relies on the joint potential and collaboration of our more than 72,000 employees around the world. We recognise the importance of the unique skills and perspectives our people bring to the table, and we work continuously to bring out the best in them. Working at Novo Nordisk, we’re working toward something bigger than ourselves, and it’s a collective effort. Join us! Together, we go further. Together, we’re life changing.

Contact and Deadline
For further information please visit our www.novonordisk.com/careers or contact Kate Short at ksho@novonordkis.com. Candidates must apply by 25 April 2025 to be considered for the opportunity. 
 

We commit to an inclusive recruitment process and equality of opportunity for all our job applicants. 

At Novo Nordisk we recognize that it is no longer good enough to aspire to be the best company in the world. We need to aspire to be the best company for the world and we know that this is only possible with talented employees with diverse perspectives, backgrounds and cultures. We are therefore committed to creating an inclusive culture that celebrates the diversity of our employees, the patients we serve and communities we operate in. Together, we’re life changing.